Extended Data Fig. 9: Kaplan-Meier analyses to assess overall survival stratified by baseline serum IL-8 levels.

Analysis of pooled data from 1,344 patients receiving nivolumab-based therapy in 4 phase 3 trials—including patients with melanoma, renal cell carcinoma, squamous non-small cell lung cancer, and nonsquamous non-small cell lung cancer—confirmed that elevated baseline serum IL-8 levels were associated with overall survival. This association was significant after adjustment for baseline tumor burden and tumor programmed death-ligand 1 expression (P < 0.001). aOS data from patients in CheckMate trials −017, −057, −067, −025. IL, interleukin.